A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

This trial is testing a combination of natural killer (NK) cell therapy — immune cells engineered to fight cancer — together with an immunotherapy drug called atezolizumab, for patients with acute myeloid leukemia (AML) that has not responded to prior treatment. **You may be eligible if...** - You have been diagnosed with AML confirmed by bone marrow biopsy - Your leukemia has either failed to respond to at least 2 prior rounds of chemotherapy, OR has relapsed after a stem cell transplant - You are in reasonably good physical condition **You may NOT be eligible if...** - You have active leukemia in the brain or spinal fluid - You have had a stem cell transplant within the past 3 months or have active graft-versus-host disease - You have uncontrolled infection or significant organ failure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.